Clinical Report: Analysis of Immune-Related Adverse Events in Cancer Patients
Overview
This study examines immune-related adverse events (irAEs) in cancer patients undergoing combination therapy with immune checkpoint inhibitors (ICIs). It identifies the incidence, characteristics, and risk factors associated with irAEs and endocrine irAEs (EirAEs), highlighting the protective role of corticosteroid use and the influence of age.
Background
Immune checkpoint inhibitors have revolutionized cancer treatment, but their combination with other therapies can lead to complex adverse event profiles. Understanding the incidence and risk factors for irAEs is crucial for optimizing patient management and improving treatment outcomes. This study provides insights into the characteristics and timing of irAEs, which are essential for clinicians to monitor and manage effectively.
38.05% of patients experienced irAEs, with 4.38% having grade ≥3 severity.
The most common irAEs were endocrine (12.12%), gastrointestinal (8.75%), and dermatological (6.73%).
Corticosteroid use was identified as a protective factor against irAEs (OR = 0.511).
Age ≥65 years was associated with a lower risk of irAEs (OR = 0.487).
Combination with targeted therapy increased the risk of EirAEs (OR = 2.888).
85.25% of irAEs occurred within the first 4 treatment cycles.
Clinical Implications
Clinicians should be vigilant for irAEs, particularly during the first few treatment cycles of ICI combination therapy. The findings suggest that corticosteroid use may mitigate the risk of irAEs, and age should be considered when assessing patient risk profiles. Early identification and management of irAEs can improve patient outcomes.
Conclusion
The study underscores the importance of monitoring for irAEs in patients receiving ICI combination therapy, with specific attention to age and corticosteroid use as significant factors. Further research is needed to validate these findings in larger, multicenter studies.
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...
